Filgotinib

Generic Name
Filgotinib
Brand Names
Jyseleca
Drug Type
Small Molecule
Chemical Formula
C21H23N5O3S
CAS Number
1206161-97-8
Unique Ingredient Identifier
3XVL385Q0M
Background

Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders. 50-70% of patients with RA are...

Indication

Filgotinib is indicated for the treatment of active moderate to severe rheumatoid arthritis alone or in combination with methotrexate. Filgotinib is currently reserved for patients who are unable to tolerate or who have not responded adequately to one or more disease-modifying anti-rheumatic drugs (DMARDS).
...

Associated Conditions
Active, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis
Associated Therapies
-
Clinical Trials
Related News

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Phase 4
Recruiting
Conditions
Rheumatoid Arthritis
Interventions
Drug: Filgotinib
Drug: Adalimumab
First Posted Date
2024-07-30
Last Posted Date
2024-08-01
Lead Sponsor
Universita di Verona
Target Recruit Count
30
Registration Number
NCT06527534
Locations
🇮🇹

Rheumatology Section, University of Verona, Verona, Italy

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

First Posted Date
2024-02-29
Last Posted Date
2024-06-26
Lead Sponsor
UMC Utrecht
Target Recruit Count
60
Registration Number
NCT06285539
Locations
🇳🇱

Hagaziekenhuis, Den Haag, Netherlands

🇳🇱

Radboud university medical center, Nijmegen, Netherlands

🇳🇱

Amsterdam UMC, Amsterdam, Netherlands

and more 3 locations

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Phase 1
Recruiting
Conditions
Juvenile Idiopathic Arthritis
Interventions
Drug: Filgotinib
First Posted Date
2024-01-24
Last Posted Date
2024-10-16
Lead Sponsor
Alfasigma S.p.A.
Target Recruit Count
10
Registration Number
NCT06222034
Locations
🇫🇷

CHU Amiens - Hopital Nord, Amiens Cedex 1, France

🇩🇪

Children's university hospital Charité, Campus Virchow, SPZ, Berlin, Germany

🇫🇷

Bicêtre University Hospital, Le Kremlin Bicêtre, France

and more 6 locations

Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Phase 1
Completed
Conditions
Bioavailability
Interventions
Drug: Filgotinib
First Posted Date
2023-09-21
Last Posted Date
2023-11-29
Lead Sponsor
Galapagos NV
Target Recruit Count
12
Registration Number
NCT06043739
Locations
🇨🇦

Altasciences, Montréal, Canada

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

Recruiting
Conditions
Ulcerative Colitis
Interventions
Drug: Filgotinib
First Posted Date
2023-04-18
Last Posted Date
2024-12-16
Lead Sponsor
Alfasigma S.p.A.
Target Recruit Count
600
Registration Number
NCT05817942
Locations
🇩🇪

Synesis GmbH, Grünwald, Bavaria, Germany

🇪🇸

Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain

🇦🇹

LKH - Universitätsklinikum Graz, Graz, Austria

and more 72 locations

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

Phase 3
Active, not recruiting
Conditions
Axial Spondyloarthritis
Interventions
Drug: Filgotinib
Drug: Placebo
First Posted Date
2023-03-27
Last Posted Date
2024-12-17
Lead Sponsor
Alfasigma S.p.A.
Target Recruit Count
495
Registration Number
NCT05785611
Locations
🇧🇬

Medical Center Teodora, Ruse, Bulgaria

🇧🇪

Cliniques Universitaires de Bruxelles Hopital Erasme, Brussels, Belgium

🇧🇪

ReumaClinic, Genk, Belgium

and more 126 locations

Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis

Phase 4
Not yet recruiting
Conditions
Rheumatoid Arthritis
Interventions
Drug: Adalimumab
Drug: Filgotinib
First Posted Date
2022-08-16
Last Posted Date
2022-08-16
Lead Sponsor
Leiden University Medical Center
Target Recruit Count
40
Registration Number
NCT05502731
Locations
🇳🇱

Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

Phase 3
Terminated
Conditions
Ulcerative Colitis
Interventions
Drug: Filgotinib
Drug: Placebo
First Posted Date
2022-07-29
Last Posted Date
2024-10-04
Lead Sponsor
Galapagos NV
Target Recruit Count
22
Registration Number
NCT05479058
Locations
🇧🇪

Universitair Ziekenhuis Leuven Campus Gasthuisberg, Leuven, Belgium

🇫🇷

CHU Amiens-Picardie, Amiens, France

🇫🇷

Hôpital Pontchaillou, Rennes, France

and more 47 locations

Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

Active, not recruiting
Conditions
Rheumatoid Arthritis
Interventions
Drug: Filgotinib
First Posted Date
2022-04-12
Last Posted Date
2024-12-16
Lead Sponsor
Alfasigma S.p.A.
Target Recruit Count
155
Registration Number
NCT05323591
Locations
🇫🇷

CHU Amiens Picardie site Nord, Amiens, France

🇫🇷

CHU de Amiens Picardie, Amiens, France

🇫🇷

Hopital Avicenne AP-HP, Bobigny, France

and more 14 locations

Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)

First Posted Date
2021-08-02
Last Posted Date
2021-08-02
Lead Sponsor
R.Bos
Target Recruit Count
100
Registration Number
NCT04985435
Locations
🇳🇱

Medical Center Leeuwarden MCL, Leeuwarden, Netherlands

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy